Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Velabs Therapeutics, a Germany-based biotechnology spinout of European Molecular Biology Laboratory (EMBL), secured €3m ($3.5m) in series B funding yesterday from undisclosed backers. The spinout uses microfluidic technology to test millions of antibodies for their therapeutics effects, working both in partnership with pharmaceutical firms and building its own pipeline of assets. Velabs will use the money to advance its antibody screening program and support its pipeline of preclinical candidates for a range of diseases with limited treatment options. Velabs has…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
